{
    "clinical_study": {
        "@rank": "139626", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide 1.8 mg + metformin", 
                "arm_group_type": "Experimental", 
                "description": "2-week screening period, 26-week treatment duration, and a 1-week follow-up period"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg + metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "2-week screening period, 26-week treatment duration, and a 1-week follow-up period"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and\n      safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese\n      subjects with type 2 diabetes inadequately controlled on metformin monotherapy. Eligible\n      subjects will continue their metformin background treatment during the trial."
        }, 
        "brief_title": "The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age at least 18 years and below 80 years at the time of signing\n             informed consent\n\n          -  Subjects diagnosed type 2 diabetes mellitus and treated with metformin monotherapy at\n             a stable dose of at least 1500 mg daily or maximum tolerated dose above or equal to\n             1000 mg daily for at least 60 days prior to screening\n\n          -  HbA1c 7.0-10.0% (both inclusive)\n\n          -  Body mass index below or equal to 45.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Treatment with glucose lowering agent(s) other than stated in the inclusion criteria\n             in a period of 60 days prior to screening. An exception is short-term treatment\n             (below or equal to 7 days in total) with insulin in connection with intercurrent\n             illness\n\n          -  History of chronic pancreatitis or idiopathic acute pancreatitis\n\n          -  Any chronic disorder or severe disease which at the discretion of the investigator\n             might jeopardise subject's safety or compliance with the protocol\n\n          -  Screening calcitonin value above or equal to 50 ng/l\n\n          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine\n             neoplasia syndrome type 2\n\n          -  Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin\n             cancer or squamous cell skin cancer)\n\n          -  Any contraindications to liraglutide, sitagliptin or metformin according to local\n             labelling"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "368", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008682", 
            "org_study_id": "NN2211-4075", 
            "secondary_id": "U1111-1139-0016"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide 1.8 mg + metformin", 
                "description": "Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.", 
                "intervention_name": "liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg + metformin", 
                "description": "Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.", 
                "intervention_name": "sitagliptin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sitagliptin", 
                "Metformin", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100853"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA\u2122)", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in glycosylated haemoglobin (HbA1c)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008682"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Change from baseline in 7-point self-measured plasma glucose profile", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Subjects who achieve (yes/no) HbA1c below  7.0 % (American Diabetes Association target)", 
                "safety_issue": "No", 
                "time_frame": "After 26 weeks of treatment"
            }, 
            {
                "measure": "Subjects who achieve (yes/no) HbA1c below or equal to 6.5 % (American Association of Clinical Endocrinologists target)", 
                "safety_issue": "No", 
                "time_frame": "After 26 weeks of treatment"
            }, 
            {
                "measure": "Number of confirmed hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0-26"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}